Form 4: RA Capital Boosts Stake in Mineralys Therapeutics with $17.5 Million Purchase

RA Capital Management and related entities acquired 1,296,296 shares of Mineralys Therapeutics at $13.50 per share, increasing their indirect holdings.

Summary

• RA Capital Management, L.P., along with related entities including RA Capital Healthcare Fund, L.P., RA Capital Nexus Fund III, L.P., Peter Kolchinsky, and Rajeev M. Shah, filed a Form 4 detailing changes in beneficial ownership of Mineralys Therapeutics, Inc. (MLYS) common stock.
• On March 13, 2025, RA Capital Healthcare Fund, L.P. purchased 1,296,296 shares of MLYS common stock at a price of $13.50 per share.
• Following this transaction, the total number of shares beneficially owned indirectly by RA Capital Management, L.P. is 4,280,051, held by the RA Capital Healthcare Fund, L.P.
• RA Capital Nexus Fund III, L.P. holds 1,867,229 shares.
• RA Capital Management, L.P., as the investment manager for the Fund and Nexus Fund III, disclaims beneficial ownership except to the extent of their pecuniary interest.
• Peter Kolchinsky and Rajeev Shah, as managing members of RA Capital Management GP, LLC, also disclaim beneficial ownership except to the extent of their pecuniary interest.
• Dr. Derek DiRocco, a Partner of the Adviser, serves on the Issuer's board of directors.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of a transaction. The increased investment could be seen as a positive, but it's not explicitly stated as such.

Positives

• RA Capital's increased investment in Mineralys Therapeutics could be seen as a positive signal about the company's prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when significant changes in ownership occur, providing transparency to the market regarding insider transactions.

Stakeholder Impact

• The increased stake by RA Capital could positively influence shareholder confidence.

Key Dates